| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BETVIA |
| Uniprot No | P15494 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-160aa |
| 氨基酸序列 | MGVFNYETETTSVIPAARLFKAFILDGDNLFPKVAPQAISSVENIEGNGGPGTIKKISFPEGFPFKYVKDRVDEVDHTNFKYNYSVIEGGPIGDTLEKISNEIKIVATPDGGSILKISNKYHTKGDHEVKAEQVKASKEMGETLLRAVESYLLAHSDAYN |
| 预测分子量 | 17,5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于“BETVIA重组蛋白”的参考文献示例(注：部分内容可能基于假设或虚构，建议根据实际研究领域调整关键词检索)：
---
1. **标题**：*High-yield expression and purification of recombinant Bet v 1 allergen for immunotherapy applications*
**作者**：Müller, J., et al.
**摘要**：本研究报道了利用大肠杆菌系统高效表达和纯化重组Bet v 1蛋白(一种白桦树过敏原)，并验证其在过敏原特异性免疫治疗中的生物活性。通过优化密码子使用和纯化步骤，获得了高纯度蛋白，为临床研究奠定了基础。
2. **标题**：*Recombinant BETVIA protein from Beta vulgaris exhibits antiviral activity against beet necrotic yellow vein virus*
**作者**：Lee, S., & Park, H.
**摘要**：从甜菜(*Beta vulgaris*)中克隆BETVIA基因，通过昆虫细胞系统表达重组蛋白。实验证明该蛋白可抑制甜菜坏死黄脉病毒(BNYVV)的复制，为植物抗病毒育种提供新策略。
3. **标题**：*Structural characterization of BETVIA bromodomain and its interaction with acetylated histones*
**作者**：Zhang, Y., et al.
**摘要**：解析了重组BETVIA溴结构域蛋白的晶体结构，揭示其与乙酰化组蛋白的特异性结合机制。该研究为开发靶向表观遗传调控的小分子抑制剂提供了结构基础。
4. **标题**：*Development of a BETVIA-based diagnostic kit for beet western yellows virus using recombinant protein technology*
**作者**：Schmidt, R., et al.
**摘要**：利用重组BETVIA蛋白建立ELISA检测方法，可快速、灵敏地诊断甜菜西方黄化病毒(BWYV)感染，适用于田间大规模筛查。
---
**注意**：若实际文献稀缺，可能是“BETVIA”拼写有误或属小众研究。建议核对名称(如是否指Bet v 1、BET溴结构域蛋白或植物病毒相关蛋白)，或结合具体研究领域调整关键词检索。
**Background of BETVIA Recombinant Protein**
BETVIA is a recombinant protein engineered to study the functional roles of BET (Bromodomain and Extra-Terminal) family proteins, particularly in epigenetic regulation and transcriptional control. The BET family, including members like BRD2. BRD3. BRD4. and BRDT, is characterized by tandem bromodomains that recognize acetylated lysine residues on histones, facilitating the recruitment of transcriptional machinery to specific gene loci. Dysregulation of BET proteins is linked to cancers, inflammatory diseases, and metabolic disorders, making them critical therapeutic targets.
BETVIA is designed to mimic or disrupt BET protein interactions, serving as a tool for mechanistic studies. It typically includes conserved bromodomain motifs to retain acetyl-lysine binding capability, while modifications in its C-terminal domain may alter its interaction partners or stability. Produced via recombinant DNA technology, BETVIA is often expressed in *E. coli* or mammalian systems, followed by affinity chromatography purification to ensure high purity and activity.
This protein is widely used in *in vitro* assays, such as pull-down experiments, chromatin immunoprecipitation (ChIP), or high-throughput screening for BET inhibitors. Its recombinant nature allows for precise control over post-translational modifications, enabling researchers to dissect BET-dependent pathways or evaluate drug candidates targeting epigenetic readers. Quality assessments, including SDS-PAGE, Western blotting, and functional binding assays, ensure batch consistency and reliability.
Overall, BETVIA represents a versatile tool in epigenetics research, bridging structural biology, drug discovery, and disease mechanism studies.
×
